Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

NCT00280098 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: docetaxel

Sponsor

Sanofi